|Molecule Type||Antigen Expression||Molecular Weight|
Min / Max
|Non-lineage Restricted Molecule|
|CD65s is expressed on granulocytes, monocytes, myeloid leukemia cells, AML blasts and some ALL blasts. Aberrant expression is on some acute lymphatic leukemias. |
|MOLECULAR FAMILY NAME: |
CD65s contains a type-2 carbohydrate chain and is a fucoganglioside with 4 lactosamine repeats, 1 fucose bound to the penultimate N-acetylglucosamine and 1 terminal a2,3 linked N-acetylneuraminic acid.
The recognized carbohydrate structure is carried by glycolipids and glycoproteins and is probably also by several proteins but the Mr of proteins is unknown.
POST-TRANSCRIPTIONAL MODIFICATION: No information.
POST-TRANSLATIONAL MODIFICATION: No information.
|LIGANDS AND MOLECULES ASSOCIATED WITH CD65s|
Some investigators observed clear interactions with E-selectins or P-selectins, while others found no evidence for that.
CD65s has been described to inhibit phagocytosis and to induce phagocyte calcium flux and oxidative burst. CD65s appears when CD34 disappears during myeloid differentiation.
BIOCHEMICAL ACTIVITY: No information.
DISEASE RELEVANCE AND FUNCTION OF CD65s IN INTACT ANIMAL
CD66s is widely used as a marker for acute leukemia cell typing and helps to identify a subset of pre-pre-B ALL.
|MOLECULAR INTERACTIONS -|
PROTEINS AND DNA ELEMENTS WHICH REGULATE TRANSCRIPTION OF CD65s: No information.
SUBSTRATES: No information.
ENZYMES WHICH MODIFY CD65s: No information.
The situation for CD65s and CD65 is now very similar to the CD15s/CD15 distinction in that 1 antibody, VIM2, selectively recognizes the sialylated form, while all others so far identified CD65 antibodies and preferentially bind to the non-sialylated form.
Database accession numbers
Revised June 25, 2008